10.06.2024 | ASO Research Letter
Outcomes of Merkel Cell Carcinoma in the Era of Immune Checkpoint Blockade
verfasst von:
Neha Shafique, MD, Anushka Dheer, BA, Gabriella Tortorello, MD, Emily Y. Chu, MD, PhD, Michael E. Ming, MD, MSCE, John T. Miura, MD, Giorgos C. Karakousis, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 9/2024
Einloggen, um Zugang zu erhalten
Excerpt
Merkel cell carcinoma (MCC) is a rare neuroendocrine-like tumor of the skin with a historically dismal prognosis.
1,2 The advent of immune checkpoint blockade (ICB) agents has led to a marked improvement in the recurrence and survival rates for metastatic MCC as demonstrated in multiple clinical trials.
3 Despite these promising results, there is a lack of real-world data on the overall impact of these newer immunotherapies on patients with MCC. We examine a national cohort to assess the impact of ICB on the prognosis for MCC, which can inform clinicians in counseling patients with this rare skin cancer. …